Fig. 9

The effects of bilirubin on the total volume of heart structures. (A) Myocardium (B) Endocardium, (C) Vessels. Control = Normal rats; Bilirubin = Healthy rats received bilirubin; AS = Atherosclerosis model; AS + BR-6 (a.k.a. Treated group) = Atherosclerosis model received HFD + STZ + bilirubin (for 6 weeks); AS + BR-14 = Atherosclerosis model received HFD + STZ + bilirubin (for 14 weeks) (a.k.a. Protected group). All values ​​are expressed as mean ± standard deviation (n = 6). Statistical analysis was determined using the Kruskal-Wallis test with Dunn’s multiple comparisons post hoc analysis